ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Allogene Therapeutics Inc (ALLO) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown recent price momentum and bullish technical indicators, the financial performance is weak, insiders are selling significantly, and there are no recent positive news catalysts. The options data suggests low bearish sentiment, but the lack of strong institutional interest and poor financials outweigh the short-term technical positives.
The stock is showing bullish momentum with MACD above 0 and expanding positively, RSI at 85.114 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). However, the stock is nearing a resistance level at R2: 2.885, which may limit further upside in the short term.
and confidence in clinical trial timelines. The stock has shown strong price momentum recently, with a 7.91% gain in the last trading session.
Insiders are selling heavily, with a 723.44% increase in selling activity over the last month. Financial performance is weak, with declining net income (-37.55% YoY) and EPS (-40.62% YoY). No recent news or congress trading data to support the stock.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$41.4M (-37.55% YoY), and an EPS decline of -40.62% YoY. Gross margin dropped to 0, indicating no profitability.
Analysts have recently upgraded the stock to 'Outperform' and 'Buy' with price targets of $5 and $8, citing confidence in clinical trial timelines and potential peak sales of $1B by 2033 for cema-cel. However, the stock is still considered speculative and part of a broader biotech recovery theme.
